Dupre et al also studied the effects of GLP-1 on glucagon suppression by administering exenatide to patients with type-1 diabetes
The suppression of food intake can be attributed to three key factors: increased satiation, reduced appetitive drive, and visceral malaise after large meals in a minority of subjects [79]
A third, recent study in JAMA Network Open , from August of 2025, analyzed data from 159,000 people with type 2 diabetes who took semaglutide or tirzepatide (Mounjaro, Zepbound)
Between 2022 and 2023, the study estimated that roughly 24,500 ER visits were related to these medications
Analysts at Jeffries are predicting that the expanded use of GLP-1 obesity drugs may reduce fuel consumption, which could translate into lower costs for airplane tickets, as Fox Business has reported
COMBI: metformin 1000 mg BID + liraglutide 1.2 mg/day (COMBI: n = 11) [61]